Kraskowski, Oliver
Stratmann, Jan A.
Wiesweg, Marcel
Eberhardt, Wilfried
Metzenmacher, Martin
Schmid, Kurt W.
Herold, Thomas
Schildhaus, Hans-Ulrich
Darwiche, Kaid
Aigner, Clemens
Stuschke, Martin
Laue, Katharina
Zaun, Gregor
Kasper, Stefan
Hense, Jörg
Sebastian, Martin
Schuler, Martin
Pogorzelski, Michael
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 13 December 2022
Accepted: 3 May 2023
First Online: 18 May 2023
Declarations
:
: Martin Schuler: Consultancy: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Lilly, Novartis; honoraria for CME presentations: Alexion, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Lilly, Novartis; research funding to institution: Boehringer Ingelheim, Bristol-Myers Squibb, Novartis; other: Universität Duisburg-Essen (patents). Martin Metzenmacher: honoraria: Astra Zeneca, BMS, Boehringer Ingelheim, MSD, Novartis, Pfizer Roche, Sanofi Aventis. Marcel Wiesweg: honoraria: Amgen, Boehringer Ingelheim, Novartis, Roche, Takeda. Research. Stefan Kasper: consultancy, honoraria and travel support: Roche, Bristol-Myers Squibb, Merck Sharp and Dohme, Amgen, Merck Serono, Sanofi Aventis, Astra Zeneca, Janssen, Pharmaceuticals, Celgene, Lilly, and Servier. Michael Pogorzelski: consultancy, honoraria, and travel support: Boehringer Ingelheim, Bristol-Myers Squibb, Merck Healthcare KGaA, Merck Sharp, and Dohme, Takeda. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: The study was approved by the Ethics Committees of the Medical Faculty of the University Duisburg-Essen and University of Frankfurt in compliance with the Helsinki Declaration (Decision number: 19–8585-BO).